A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
keskiviikko 16. syyskuuta 2026 päivittänyt: AbbVie
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body.
ABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan.
Participants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results.
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.
Tutkimuksen yleiskatsaus
Tila
Rekrytointi
Ehdot
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
210
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: ABBVIE CALL CENTER
- Puhelinnumero: 844-663-3742
- Sähköposti: abbvieclinicaltrials@abbvie.com
Opiskelupaikat
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100053
- Rekrytointi
- Xuanwu Hospital Capital Medical University /ID# 283310
-
-
Guangdong
-
Guangzhou, Guangdong, Kiina, 510260
- Rekrytointi
- The Second Affiliated Hospital of Guangzhou Medical University /ID# 284295
-
-
-
-
California
-
Irvine, California, Yhdysvallat, 92614
- Rekrytointi
- Irvine Center for Clinical Research /ID# 277752
-
-
Colorado
-
Boulder, Colorado, Yhdysvallat, 80301
- Rekrytointi
- Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856
-
-
Florida
-
Bradenton, Florida, Yhdysvallat, 34207
- Rekrytointi
- Key Clinical Research LLC /ID# 277800
-
Ottaa yhteyttä:
- Site Coordinator
- Puhelinnumero: 941-241-5539
-
Clermont, Florida, Yhdysvallat, 34711
- Rekrytointi
- K2 Medical Research - Clermont /ID# 277859
-
Lady Lake, Florida, Yhdysvallat, 32159
- Rekrytointi
- K2 Medical Research - The Villages /ID# 278290
-
Stuart, Florida, Yhdysvallat, 34997
- Rekrytointi
- Alzheimer'S Research And Treatment Center - Stuart /ID# 278206
-
Wellington, Florida, Yhdysvallat, 33414
- Rekrytointi
- Alzheimer's Research And Treatment Center - Wellington /ID# 277749
-
Ottaa yhteyttä:
- Site Coordinator
- Puhelinnumero: (561) 209-2400
-
Winter Park, Florida, Yhdysvallat, 32789
- Rekrytointi
- Conquest Research - Winter Park /ID# 277760
-
Ottaa yhteyttä:
- Site Coordinator
- Puhelinnumero: 407-916-0060
-
-
Massachusetts
-
Watertown, Massachusetts, Yhdysvallat, 02472
- Rekrytointi
- Adams Clinical /ID# 277754
-
-
Tennessee
-
Cordova, Tennessee, Yhdysvallat, 38018
- Rekrytointi
- Neurology Clinic - Cordova /ID# 277790
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75231
- Rekrytointi
- Kerwin Medical Center /ID# 277788
-
Ottaa yhteyttä:
- Site Coordinator
- Puhelinnumero: 972-433-9100
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Kuvaus
Inclusion Criteria:
Participants meeting all the following criteria for Alzheimer's disease (AD):
- In regions where timely testing is feasible (e.g., results available within 4 weeks of Visit 1), plasma biomarker that is predictive of elevated brain amyloid at Screening for participants that do not have known elevated brain amyloid based on previous amyloid positron emission tomography (PET) results.
- Participants with amyloid positron emission tomography PET scan results consistent with significant amyloid pathology (as determined by a Centiloid value of 50 or higher).
- Participants must have a Mini-Mental State Examination (MMSE) score of 20 or higher at Screening.
Exclusion Criteria:
- Participants with screening magnetic resonance imaging (MRI) that show evidence of another potential etiology for progressive dementia.
- Participants who have any current serious conditions or illnesses that are not adequately controlled, or any conditions that, in the investigator's opinion, could interfere with the analyses in this study, including but not limited to psychiatric, neurologic (other than AD), cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, immunologic, or hematologic, metabolic, pulmonary, ophthalmologic, dermatologic, and/or any history of abnormal laboratory results that are indicative of significant disease(s).
- Participants who had prior exposure to ABBV-1758 or any history of exposure to anti-amyloid beta monoclonal antibody (mAb) treatment.
Participants with other significant pathological findings on brain MRI at screening, including but not limited to:
- Evidence of vasogenic edema
- 4 or more microhemorrhages (defined as 10 mm or less at the greatest diameter)
- Any macrohemorrhage (defined as greater than 10 mm at the greatest diameter)
- Any superficial siderosis
- Severe white matter disease
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Stage A-ABBV-1758 Dose A
Participants will receive ABBV-1758 dose A once every 4 weeks (Q4W).
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage A-ABBV-1758 Dose B
Participants will receive ABBV-1758 dose B Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage A-ABBV-1758 Dose C
Participants will receive ABBV-1758 dose C Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage A-ABBV-1758 Dose D
Participants will receive ABBV-1758 dose D Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage B- ABBV-1758 - Expanded Cohort 1
Participants will receive ABBV-1758 dose determined in Stage A Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage B- ABBV-1758- Expanded Cohort 2
Participants will receive ABBV-1758 dose determined in Stage A Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage C- ABBV-1758 - Japanese Cohort 1
Participants will receive ABBV-1758 dose determined in Stage A Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage C- ABBV-1758- Japanese Cohort 2
Participants will receive ABBV-1758 dose determined in Stage A Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Kokeellinen: Stage C- ABBV-1758-Chinese Cohort
Participants will receive ABBV-1758 dose determined in Stage A Q4W.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758 Dose A
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758 Dose B
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758 Dose C
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758 Dose D
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758 - Expanded Cohort 1
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758- Expanded Cohort 2
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758 - Japanese Cohort 1
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758- Japanese Cohort 2
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
|
Placebo Comparator: Placebo for ABBV-1758- Chinese Cohort
Participants will receive Placebo for ABBV-1758.
|
Intravenous (IV) or Subcutaneous (SC)
Subcutaneous (SC)
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of Participants Experiencing Adverse Events (AEs)
Aikaikkuna: Up to approximately 40 weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment.
The investigator assesses the relationship of each event to the use of study drug.
|
Up to approximately 40 weeks
|
|
Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results
Aikaikkuna: Up to approximately 40 weeks
|
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.
|
Up to approximately 40 weeks
|
|
Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA)
Aikaikkuna: Up to approximately 40 weeks
|
Amyloid related imaging abnormalities represent a spectrum of magnetic resonance imaging findings primarily observed in participants undergoing treatment with anti-amyloid therapies.
|
Up to approximately 40 weeks
|
|
Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Aikaikkuna: Up to approximately 40 weeks
|
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.
|
Up to approximately 40 weeks
|
|
Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) Parameters
Aikaikkuna: Up to approximately 40 weeks
|
12-lead resting ECGs will be recorded.
Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).
|
Up to approximately 40 weeks
|
|
Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Aikaikkuna: Up to approximately 40 weeks
|
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.
|
Up to approximately 40 weeks
|
|
Stage A, B, and C: Change from Baseline in Brain Amyloid Load
Aikaikkuna: Up to approximately 28 Weeks
|
Measured by amyloid positron emission tomography (PET)
|
Up to approximately 28 Weeks
|
|
Stage A and C: Maximum Plasma Concentration (Cmax) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
Cmax of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Time to Cmax (Tmax) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
Tmax of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Trough Concentration measured at the end of a dosing interval at steady state (Ctrough) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
Ctrough of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
AUCtau of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Average Serum Concentration at Steady-State (Cav,ss) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
Cav,ss of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Accumulation ratio for (AUCtau) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
AUCtau of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Total Body Clearance (CL) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
CL of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Apparent Clearance (CL/F) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
CL/F of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Volume of Distribution at Steady-State (Vss)
Aikaikkuna: Up to approximately 40 weeks
|
Vss of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Apparent Volume of Distribution during the Terminal Phase (Vz)
Aikaikkuna: Up to approximately 40 weeks
|
Vz of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Terminal Phase Elimination Rate Constant (β) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
β of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1758
Aikaikkuna: Up to approximately 40 weeks
|
Terminal phase elimination half-life of ABBV-1758
|
Up to approximately 40 weeks
|
|
Stage A and C: Effective Half-Life (T1/2,eff)
Aikaikkuna: Up to approximately 40 weeks
|
T1/2,eff of ABBV-1758
|
Up to approximately 40 weeks
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Opintojohtaja: ABBVIE INC., AbbVie
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Perjantai 15. toukokuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Tiistai 1. lokakuuta 2030
Opintojen valmistuminen (Arvioitu)
Tiistai 1. lokakuuta 2030
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Perjantai 15. toukokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Perjantai 15. toukokuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Keskiviikko 20. toukokuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Perjantai 18. syyskuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Keskiviikko 16. syyskuuta 2026
Viimeksi vahvistettu
Tiistai 1. syyskuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- M25-804
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
JOO
IPD-suunnitelman kuvaus
AbbVie is committed to responsible clinical trial data sharing.
This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-jaon aikakehys
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-jaon käyttöoikeuskriteerit
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Joo
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Yhdysvalloissa valmistettu ja sieltä viety tuote
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .